Training for assessment of negative symptoms of schizophrenia across languages and cultures: Comparison of the NSA-16 with the PANSS negative subscale and negative symptom factor

Clinical Schizophrenia and Related Psychoses

Volumn 5, Issue 2, 2011, Pages 87-94

  Daniel, David G ^a   Alphs, Larry ^b   Cazorla, Pilar ^c   Bartko, John J ^d   Panagides, John ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE

Author keywords

Marder negative factor; Negative symptoms; NSA; PANSS negative subscale; Rating scales; Schizophrenia

Indexed keywords

ARTICLE; AUSTRALIA; CALCULATION; CENTRAL AMERICA; CULTURAL FACTOR; EASTERN EUROPE; EDUCATION; HUMAN; LANGUAGE; NEGATIVE SYNDROME; NORTH AMERICA; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; SIXTEEN ITEM NEGATIVE SYMPTOM ASSESSMENT SCALE; SOUTH AFRICA; SOUTH AMERICA; WESTERN EUROPE; BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; INTERNATIONAL COOPERATION; MULTICENTER STUDY; OBSERVER VARIATION; PSYCHOLOGIC TEST; REPRODUCIBILITY; SCHIZOPHRENIA; STANDARD; VOCATIONAL EDUCATION;

BEHAVIORAL SYMPTOMS; EDUCATION, PROFESSIONAL; HUMANS; INTERNATIONALITY; OBSERVER VARIATION; PSYCHOLOGICAL TESTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 80052152783     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.5.2.5     Document Type: Article

References (28)

1. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res 1995;14(3):229-234.
2. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58(12):538-546. (Pubitemid 28100274)
3. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006;32(2):238-245.
4. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48(3):239-246.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
6. Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull 2005;31(4):910-921. (Pubitemid 41437786)
7. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31(9):2033-2046.
8. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162(3):495-506. (Pubitemid 40343916)
9. Gladsjo JA, McAdams LA, Palmer BW, Moore DJ, Jeste DV, Heaton RK. A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity. Schizophr Bull 2004;30(4):739-754. (Pubitemid 40469511)
10. Revheim N, Schechter I, Kim D, Silipo G, Allingham B, Butler P, et al. Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophr Res 2006;83(2-3):237-245.
11. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153(3):321-330. (Pubitemid 26074706)
12. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45(3):175-184.
13. McGurk SR, Mueser KT, Harvey PD, LaPuglia R, Marder J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr Serv 2003;54(8):1129-1135. (Pubitemid 36951514)
14. Rush AJ, First MB, Blacker D, editors. Handbook of psychiatric measures. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc.; 2007.
15. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32(2):214-219.
16. Eckert SL, Diamond PM, Miller AL, Velligan DI, Funderburg LG, True JE. A comparison of instrument sensitivity to negative symptom change. Psychiatry Res 1996;63(1):67-75. (Pubitemid 26228649)
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-276. (Pubitemid 18039085)
18. Kay SR, Opler LA, Fiszbein A, Ramirez PM, Opler M, White L. Positive and negative syndrome scale (PANSS) technical manual. Toronto, Ontario: Multi-Health Systems, Inc.; 2006.
19. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptom assessment. J Psychiatr Res 1993;27(3):253-258. (Pubitemid 23344946)
20. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989;25(2):159-163. (Pubitemid 19273137)
21. Axelrod BN, Alphs LD. Training novice raters on the Negative Symptom Assessment Scale. Schizophr Res 1993;9(1):25-28. (Pubitemid 23076886)
22. Axelrod BN, Goldman RS, Woodard JL, Alphs LD. Factor structure of the negative symptom assessment. Psychiatry Res 1994;52(2):173-179. (Pubitemid 24173291)
23. Acquadro C, Conway K, Hareendran A, Aaronson N; European Regulatory Issues and Quality of Life Assessment (ERIQA) Group. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health 2008;11(3):509-521. (Pubitemid 351712980)
24. Arnold LM, Keck PE Jr, Collins J, Wilson R, Fleck DE, Corey KB, et al. Ethnicity and first-rank symptoms in patients with psychosis. Schizophr Res 2004;67(2-3):207-212. (Pubitemid 38251450)
25. Draguns JG, Tanaka-Matsumi J. Assessment of psychopathology across and within cultures: issues and findings. Behav Res Ther 2003;41(7):755-776. (Pubitemid 36638252)
26. Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiatry 2000;47(8):762-766. (Pubitemid 30201674)
27. Müller MJ, Szegedi A. Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials. J Clin Psychopharmacol 2002;22(3):318-325. (Pubitemid 34546848)
28. Rubio-Stipec M, Hsia-Rei Hicks M, Tsuang MT. Cultural factors influencing the selection, use and interpretation of psychiatric measures. In: Rush AJ Jr, First MB, Blacker D, editors. Handbook of psychiatric measures: American Psychiatric Publishing, Inc.; 2000. p. 33-41.